Zhejiang Cancer Hospital
🇨🇳China
A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 118
- Registration Number
- NCT05183958
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT05160727
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer
Phase 4
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 606
- Registration Number
- NCT05148767
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05131841
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Immune Score Based Radiomics in Nasopharyngeal Carcinoma
Recruiting
- Conditions
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 494
- Registration Number
- NCT05126160
- Locations
- 🇨🇳
Ningbo Medical Center Lihuili Hospital, Ningbo, Ningbo, China
🇨🇳The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Wenzhou, China
🇨🇳Renmin Hospital of Wuhan University, Wuhan, Hubei, China
PTC Guiding Neoadjuvant Treatment in Breast Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT05103293
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Dendrobium Huoshanense Suppository in Rectal Cancer
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 168
- Registration Number
- NCT05079438
- Locations
- 🇨🇳
Ji Zhu, Hangzhou, Zhejiang, China
The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05075512
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study
Completed
- Conditions
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 14
- Registration Number
- NCT05054166
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma
Not Applicable
- Conditions
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 186
- Registration Number
- NCT05053386
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
© Copyright 2024. All Rights Reserved by MedPath